Abbott India Ltd
NSE:ABBOTINDIA
Intrinsic Value
Abbott India Ltd. engages in the development, manufacture, and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one ABBOTINDIA stock under the Base Case scenario is 13 856.7389 INR. Compared to the current market price of 25 914.9004 INR, Abbott India Ltd is Overvalued by 47%.
Valuation Backtest
Abbott India Ltd
Run backtest to discover the historical profit from buying and selling ABBOTINDIA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Abbott India Ltd
Current Assets | 29.5B |
Cash & Short-Term Investments | 643.1m |
Receivables | 3.8B |
Other Current Assets | 25.1B |
Non-Current Assets | 15.7B |
Long-Term Investments | 12.7B |
PP&E | 2.3B |
Intangibles | 69m |
Other Non-Current Assets | 609.8m |
Current Liabilities | 12.5B |
Accounts Payable | 8.9B |
Other Current Liabilities | 3.5B |
Non-Current Liabilities | 1.6B |
Long-Term Debt | 451.4m |
Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
Abbott India Ltd
Revenue
|
44.1B
INR
|
Cost of Revenue
|
-24.1B
INR
|
Gross Profit
|
20B
INR
|
Operating Expenses
|
-9.2B
INR
|
Operating Income
|
10.7B
INR
|
Other Expenses
|
-1.6B
INR
|
Net Income
|
9.1B
INR
|
Free Cash Flow Analysis
Abbott India Ltd
ABBOTINDIA Profitability Score
Profitability Due Diligence
Abbott India Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Abbott India Ltd's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
ABBOTINDIA Solvency Score
Solvency Due Diligence
Abbott India Ltd's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
Abbott India Ltd's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABBOTINDIA Price Targets Summary
Abbott India Ltd
According to Wall Street analysts, the average 1-year price target for ABBOTINDIA is 29 291.17 INR with a low forecast of 25 957 INR and a high forecast of 34 650 INR.
Shareholder Return
ABBOTINDIA Price
Abbott India Ltd
Average Annual Return | 33.14% |
Standard Deviation of Annual Returns | 29.17% |
Max Drawdown | -14% |
Market Capitalization | 546.3B INR |
Shares Outstanding | 21 250 513 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Abbott India Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 3,597 full-time employees. The firm has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. The company provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines and consumer health, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremalax (constipation), Pankreoflat (indigestion) and Duvadilan (preterm labor), among others. The company offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure and Glucerna, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one ABBOTINDIA stock under the Base Case scenario is 13 856.7389 INR.
Compared to the current market price of 25 914.9004 INR, Abbott India Ltd is Overvalued by 47%.